RhumbLine Advisers
GYRE icon

RhumbLine Advisers’s Gyre Therapeutics GYRE Stock Holding History

RhumbLine Advisers’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91.4K Sell
13,116
-916
-7% -$7.11K ﹤0.01% 3447
2025
Q4 		$99.1K Buy
14,032
+600
+4% +$4.63K ﹤0.01% 3479
2025
Q3 		$100K Sell
13,432
-2,754
-17% -$20.9K ﹤0.01% 3519
2025
Q2 		$119K Buy
16,186
+5,045
+45% +$44K ﹤0.01% 3472
2025
Q1 		$86K Buy
11,141
+709
+7% +$7.78K ﹤0.01% 3443
2024
Q4 		$126K Buy
10,432
+8
+0.1% +$102 ﹤0.01% 3404
2024
Q3 		$131K Buy
10,424
+133
+1% +$1.72K ﹤0.01% 3425
2024
Q2 		$123K Buy
+10,291
New +$141K ﹤0.01% 3453
2021
Q2 		– Sell
-4,398
Closed -$166K – 3045
2021
Q1 		$166K Buy
4,398
+440
+11% +$20.1K ﹤0.01% 2869
2020
Q4 		$187K Buy
3,958
+692
+21% +$30K ﹤0.01% 2859
2020
Q3 		$105K Buy
3,266
+371
+13% +$14.5K ﹤0.01% 2856
2020
Q2 		$127K Buy
+2,895
New +$136K ﹤0.01% 2915
2019
Q2 		– Sell
-2,243
Closed -$136K – 2983
2019
Q1 		$136K Sell
2,243
-24
-1% -$1.54K ﹤0.01% 2822
2018
Q4 		$134K Buy
2,267
+683
+43% +$50.4K ﹤0.01% 2836
2018
Q3 		$128K Buy
1,584
+35
+2% +$2.77K ﹤0.01% 2832
2018
Q2 		$136K Buy
+1,549
New +$272K ﹤0.01% 2834
2014
Q2 		– Sell
-48
Closed -$178K – 3032
2014
Q1 		$178K Sell
48
-1
-2% -$3.7K ﹤0.01% 2812
2013
Q4 		$161K Sell
49
-3
-6% -$11.8K ﹤0.01% 2885
2013
Q3 		$220K Sell
52
-1
-2% -$4.02K ﹤0.01% 2730
2013
Q2 		$178K Buy
+53
New +$202K ﹤0.01% 3039

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RhumbLine Advisers's GYRE Position: Q1 2026 in Review

RhumbLine Advisers reduced its Gyre Therapeutics (GYRE) stake by 6.5% in Q1 2026, selling an estimated $7.11K and leaving 13,116 shares worth $91.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3447.

RhumbLine Advisers first reported a position in GYRE in Q2 2013 and has held it in 20 quarters since. The position peaked at $220K in Q3 2013. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • RhumbLine Advisers held 13,116 shares of Gyre Therapeutics worth $91.4K as of Q1 2026.
  • RhumbLine Advisers sold 916 Gyre Therapeutics shares in Q1 2026, an estimated $7.11K.
  • Gyre Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3447 holding.
  • RhumbLine Advisers first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 20 quarters since.
  • RhumbLine Advisers's Gyre Therapeutics position peaked at $220K in Q3 2013.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.